Professor Hani Gabra took his medical degree at Glasgow University in 1987 and his PhD at Edinburgh University in 1996. After 5 years as clinical scientist and head of the ICRF Ovarian Cancer Cell and Molecular Genetics Laboratory in Edinburgh, he moved in 2003 to his current position as professor of medical oncology, head of the Molecular Therapeutics Unit and director of the Ovarian Cancer Action Research Centre at the Imperial College London.
Professor Gabra is the founding president of the European Translational Ovarian Cancer Network (EUTROC), a consortium of 70 centers conducting translational studies and clinical trials in ovarian cancer. He led the Ovarian Cancer Section of the Scottish Gynaecological Cancer Trials Group (SCOTROC) and was the Scottish representative to the Gynaecological Cancer Intergroup (GCIG) 2004-9. He has served on CRUK’s CTAAC national clinical trials funding committee, and currently sits on the INCa French Translational Research Funding Committee. He is a member of the editorial board of several journals.
Professor Gabra’s basic science research interests are in tumor-suppressor biology and cancer multiplatform molecular profiling and integrative OMICS. He has translational research interests in the molecular basis of ovarian cancer platinum resistance as well as all phases of clinical research in gynecological cancer.